Google Play mobile download button
Apple IOS mobile download button
Google Play mobile download button
Apple IOS mobile download button
HomeBreaking NewsMerck, Sichuan Kelun enter cancer collaboration, with milestone payments up to $9.3...

Merck, Sichuan Kelun enter cancer collaboration, with milestone payments up to $9.3 billion

'Quick read' news summary

Merck & Co. Inc. MRK, +0.12% said Thursday that it entered into an agreement with Sichuan Kelun Pharmaceutical Co. Ltd. 002422, +10.00% to develop seven new cancer therapies. Merck will pay the Chinse biotech an upfront payment of $175 million, with milestone payments worth up to $9.3 billion. Merck will also make an equity investment in the company. Merck’s stock is up 44.7% so far this year, while the S&P 500 SPX, -1.45% is down 18.6%.

Merck & Co. Inc. MRK, +0.12% said Thursday that it entered into an agreement with Sichuan Kelun Pharmaceutical Co. Ltd. 002422, +10.00% to develop seven new cancer therapies. Merck will pay the Chinse biotech an upfront payment of $175 million, with milestone payments worth up to $9.3 billion. Merck will also make an equity investment in the company.

Read different perspectives